Moody National Bank Trust Division acquired a new stake in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,075 shares of the company’s stock, valued at approximately $204,000.
A number of other large investors also recently made changes to their positions in TARO. Acadian Asset Management LLC raised its stake in Taro Pharmaceutical Industries by 136.8% during the second quarter. Acadian Asset Management LLC now owns 235,930 shares of the company’s stock valued at $27,295,000 after buying an additional 136,287 shares during the last quarter. Robeco Institutional Asset Management B.V. purchased a new position in Taro Pharmaceutical Industries during the second quarter valued at $3,838,000. Northern Trust Corp raised its stake in Taro Pharmaceutical Industries by 56.2% during the second quarter. Northern Trust Corp now owns 81,294 shares of the company’s stock valued at $9,404,000 after buying an additional 29,242 shares during the last quarter. Renaissance Technologies LLC raised its stake in Taro Pharmaceutical Industries by 9.8% during the second quarter. Renaissance Technologies LLC now owns 287,000 shares of the company’s stock valued at $33,203,000 after buying an additional 25,600 shares during the last quarter. Finally, Boston Partners purchased a new position in Taro Pharmaceutical Industries during the second quarter valued at $2,723,000. Institutional investors and hedge funds own 10.45% of the company’s stock.
TARO has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Taro Pharmaceutical Industries in a report on Friday, August 10th. Zacks Investment Research lowered Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Thursday, August 16th. Finally, ValuEngine lowered Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a report on Monday, September 24th.
Taro Pharmaceutical Industries stock opened at $101.34 on Wednesday. The firm has a market capitalization of $3.93 billion, a price-to-earnings ratio of 16.40 and a beta of 0.36. Taro Pharmaceutical Industries Ltd. has a 12 month low of $93.01 and a 12 month high of $128.46.
Taro Pharmaceutical Industries (NYSE:TARO) last posted its earnings results on Monday, November 5th. The company reported $1.60 EPS for the quarter, missing the Zacks’ consensus estimate of $1.96 by ($0.36). The business had revenue of $158.97 million during the quarter, compared to the consensus estimate of $167.40 million. Taro Pharmaceutical Industries had a return on equity of 11.73% and a net margin of 34.18%. On average, sell-side analysts expect that Taro Pharmaceutical Industries Ltd. will post 7.65 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Moody National Bank Trust Division Acquires Shares of 2,075 Taro Pharmaceutical Industries Ltd. (TARO)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/moody-national-bank-trust-division-acquires-shares-of-2075-taro-pharmaceutical-industries-ltd-taro.html.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Featured Article: Initial Public Offering (IPO)
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.